IN2014MN02513A - - Google Patents
Info
- Publication number
- IN2014MN02513A IN2014MN02513A IN2513MUN2014A IN2014MN02513A IN 2014MN02513 A IN2014MN02513 A IN 2014MN02513A IN 2513MUN2014 A IN2513MUN2014 A IN 2513MUN2014A IN 2014MN02513 A IN2014MN02513 A IN 2014MN02513A
- Authority
- IN
- India
- Prior art keywords
- subunits
- mcm
- hmcm6
- hmcm2
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644442P | 2012-05-09 | 2012-05-09 | |
| PCT/US2013/040287 WO2013169989A1 (en) | 2012-05-09 | 2013-05-09 | Method and compounds for inhibiting the mcm complex and their application in cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02513A true IN2014MN02513A (enExample) | 2015-07-17 |
Family
ID=49551267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2513MUN2014 IN2014MN02513A (enExample) | 2012-05-09 | 2013-05-09 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11648258B2 (enExample) |
| EP (2) | EP4248978A3 (enExample) |
| JP (6) | JP2015517500A (enExample) |
| CN (2) | CN110412285B (enExample) |
| AU (1) | AU2013259486B2 (enExample) |
| CA (2) | CA3111702C (enExample) |
| ES (1) | ES2949335T3 (enExample) |
| IN (1) | IN2014MN02513A (enExample) |
| WO (1) | WO2013169989A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019283946B2 (en) * | 2017-05-19 | 2021-05-20 | Enkang Pharmaceuticals (Guangzhou), Ltd. | Crystal characteristics, preparation processes and anticancer applications of 17beta-neriifolin crystal forms |
| CN108948119B (zh) | 2017-05-19 | 2023-11-21 | 恩康药业科技（广州）有限公司 | 黄夹次甙乙多晶型的晶型特征、制备方法及在抗癌上的应用 |
| CN114177189A (zh) * | 2019-03-27 | 2022-03-15 | 天津中医药大学 | 黄夹次乙苷作为抗肿瘤药物的应用 |
| WO2025077888A1 (zh) * | 2023-10-13 | 2025-04-17 | 恩康药业科技（广州）有限公司 | 一种适合外用的化合物及药物组合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0592990A (ja) | 1991-08-06 | 1993-04-16 | Taisho Pharmaceut Co Ltd | カルデノライド誘導体 |
| WO2002014343A1 (en) | 2000-08-17 | 2002-02-21 | Terness, Peter | Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents |
| US8318922B2 (en) | 2002-08-29 | 2012-11-27 | The Hong Kong Polytechnic University | Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins |
| US7393950B2 (en) | 2002-08-29 | 2008-07-01 | Hong Kong University Of Science & Technology | Antisense oligonucleotides targeted to human CDC45 |
| JP2004131435A (ja) * | 2002-10-11 | 2004-04-30 | Mitsubishi Chemicals Corp | 抗癌剤のスクリーニング方法及び組織の癌化の判定方法 |
| DE10248751A1 (de) | 2002-10-18 | 2004-05-06 | Berdel, Wolfgang E., Prof. Dr.med. | Dyslokalisationsmoleküle und deren Verwendung |
| US20070207120A1 (en) * | 2004-04-14 | 2007-09-06 | Sarah Drayton | Selective Killing Of Cancer Cells By Induction Of Acetyltransferase Via Tnf-Alpha And Il-6 |
| US20090022708A1 (en) | 2004-12-22 | 2009-01-22 | Lobie Peter E | Trefoil Factors and Methods of Treating Proliferation Disorders Using Same |
| EP1787645A1 (en) | 2005-11-18 | 2007-05-23 | Institut Curie | New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway |
| US20090018088A1 (en) * | 2006-10-27 | 2009-01-15 | University Of Louisville Research Foundation | Treating cancer with cardiac glycosides |
| CN101683359B (zh) * | 2008-09-28 | 2012-05-09 | 上海秀新臣邦医药科技有限公司 | 一种治疗肿瘤的中药组合物及其制备方法 |
| CN101726577A (zh) * | 2008-10-13 | 2010-06-09 | 中山大学 | 通过干扰巢蛋白表达来筛选抑制肿瘤增殖和促进细胞凋亡的药物的方法 |
| WO2010068247A1 (en) | 2008-12-10 | 2010-06-17 | Sloan-Kettering Institute For Cancer Research | Cardenolides for the treatment of ocular cancer |
| CN102219821A (zh) | 2011-05-05 | 2011-10-19 | 沈阳药科大学 | 一类强心苷类化合物及其抗肿瘤用途 |
-
2013
- 2013-05-09 AU AU2013259486A patent/AU2013259486B2/en active Active
- 2013-05-09 US US14/399,960 patent/US11648258B2/en active Active
- 2013-05-09 CN CN201910489605.4A patent/CN110412285B/zh active Active
- 2013-05-09 ES ES13787939T patent/ES2949335T3/es active Active
- 2013-05-09 EP EP23177484.5A patent/EP4248978A3/en active Pending
- 2013-05-09 CA CA3111702A patent/CA3111702C/en not_active Withdrawn - After Issue
- 2013-05-09 CN CN201380024370.2A patent/CN104736157B/zh active Active
- 2013-05-09 CA CA2873283A patent/CA2873283C/en active Active
- 2013-05-09 JP JP2015511684A patent/JP2015517500A/ja active Pending
- 2013-05-09 EP EP13787939.1A patent/EP2846807B1/en active Active
- 2013-05-09 IN IN2513MUN2014 patent/IN2014MN02513A/en unknown
- 2013-05-09 WO PCT/US2013/040287 patent/WO2013169989A1/en not_active Ceased
-
2018
- 2018-01-11 JP JP2018002988A patent/JP2018100274A/ja active Pending
-
2019
- 2019-12-27 JP JP2019237597A patent/JP2020073544A/ja active Pending
-
2021
- 2021-09-16 JP JP2021150771A patent/JP2021193132A/ja active Pending
-
2023
- 2023-09-21 JP JP2023154199A patent/JP2024001049A/ja active Pending
-
2025
- 2025-08-12 JP JP2025134199A patent/JP2025169320A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013259486A1 (en) | 2014-12-18 |
| EP4248978A2 (en) | 2023-09-27 |
| CA3111702C (en) | 2025-03-18 |
| EP2846807A4 (en) | 2016-07-27 |
| CA3111702A1 (en) | 2013-11-14 |
| EP2846807B1 (en) | 2023-06-07 |
| CA2873283C (en) | 2021-05-04 |
| US20150099712A1 (en) | 2015-04-09 |
| WO2013169989A1 (en) | 2013-11-14 |
| AU2013259486B2 (en) | 2019-12-12 |
| JP2021193132A (ja) | 2021-12-23 |
| JP2025169320A (ja) | 2025-11-12 |
| EP2846807A1 (en) | 2015-03-18 |
| ES2949335T3 (es) | 2023-09-27 |
| EP4248978A3 (en) | 2023-11-08 |
| CN104736157A (zh) | 2015-06-24 |
| JP2020073544A (ja) | 2020-05-14 |
| JP2018100274A (ja) | 2018-06-28 |
| JP2024001049A (ja) | 2024-01-09 |
| EP2846807C0 (en) | 2023-06-07 |
| JP2015517500A (ja) | 2015-06-22 |
| CN104736157B (zh) | 2019-06-11 |
| US11648258B2 (en) | 2023-05-16 |
| CN110412285A (zh) | 2019-11-05 |
| CA2873283A1 (en) | 2013-11-14 |
| CN110412285B (zh) | 2022-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013056148A3 (en) | Scd1 antagonists for treating cancer | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| CO2017012947A2 (es) | Inhibidores de tirosina-cinasas | |
| GB2519906A (en) | Methods and systems for detecting biological components | |
| CL2018000685A1 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx/ca | |
| MY176706A (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
| CR20130245A (es) | Medios y método para el tratamiento del linfoma difuso de células b grandes (dlbcl) | |
| TN2013000464A1 (en) | Biomarkers for hedgehog inhibitor therapy | |
| MX355758B (es) | Analogos constreñidos en el anillo como inhibidores de arginasa. | |
| PH12014501844B1 (en) | Peptidomimetic macrocycles | |
| IN2015KN00550A (enExample) | ||
| CA2864161A1 (en) | Inhibition of the glycine cleavage system for treatment of cancer | |
| MX351113B (es) | Ensayo para capturar y detectar células circulantes de mieloma múltiple de la sangre. | |
| EA201690718A1 (ru) | Способ обработки целлюлозосодержащей биомассы | |
| FR3015970B1 (fr) | Procede de traitement des boues de nature thixotropique et contenant de la matiere organique. | |
| EA201792096A2 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
| IN2014MN02513A (enExample) | ||
| EP3199638A4 (en) | Cancer cell detection method using cells of biological origin | |
| GB2514940B (en) | Process for the treatment of ash, treated ash thus obtained and uses of treated ash | |
| MY167370A (en) | Method for Treating Ballast Water and Device for Treating Ballast Water Used Therefor | |
| FI20126295A7 (fi) | Menetelmä kalsiumoksidin kuivasammutukseen | |
| EA201491727A1 (ru) | Способ лечения рака с применением ингибиторов киназы аврора | |
| EP3499228A4 (en) | METHOD FOR DETECTING CIRCULATING TUMOR CELLS AND PRE-TREATMENT METHOD FOR DETECTING CIRCULATING TUMOR CELLS | |
| PL3469086T3 (pl) | Sposób obróbki i wytwarzania energii z biomas |